Lenvatinib enhances antitumor immunity of anti-PD-1 antibody
Author:
Open Access
- 22 February 2025
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (4) , 666-673
Abstract
Lenvatinib is an orally available multi-tyrosine kinase inhibitor that mainly targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) signaling. These inhibitory activities of lenvatinib exhibit antitumor efficacy, mainly due to their repressive effects on angiogenesis. In addition, a recent non-clinical evaluation using mouse tumor models revealed that lenvatinib causes immunomodulatory effects, including activation of effector T-cells and regulation of tumor-associated macrophages (TAMs). Combined treatment with lenvatinib and anti-programmed cell death-1 antibody (anti-PD-1) resulted in enhanced antitumor activity relative to monotreatment with anti-PD-1 or lenvatinib. This review summarizes the antitumor mechanisms of lenvatinib and of lenvatinib plus anti-PD-1 combination therapy.Keywords
This publication has 57 references indexed in Scilit:
- The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.2009
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patientsCancer Immunology, Immunotherapy, 2008
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2Cancer Immunology, Immunotherapy, 2006
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences, 2002
- Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humansBlood, 2001
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992
- Successful Treatment of an Angiogenic DiseaseNew England Journal of Medicine, 1989